Eli Lilly said on Thursday a long-acting form of its schizophrenia drug Zyprexa will likely become available in the United States in the "near future," based on favorable signals from U.S. regulators.
Chief Executive John Lechleiter said Lilly's optimism is based on recent meetings between the company and the Food and Drug Administration, which in February had rejected the injectable form of Lilly's biggest-selling medicine.
The FDA, in issuing its "not approvable" letter, had said it needed more information to better understand the risk and underlying cause of excessive sedation seen in about 1 percent of patients given the injectable formulation in clinical trials.
More at Reuters
No comments:
Post a Comment